Exact Sciences Corp (EXAS)

NasdaqCM: EXAS · Currency not recorded

—

Coverage state: Latest published research available

Market snapshot time is not recorded. Latest published research analyzed 2026-05-13 · stale · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh EXAS analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-13

Our latest published analysis: EXAS rated Hold

EXAS is rated Hold at $104.91 versus the reconciled fair value midpoint of $114.04, implying +8.70% upside/downside. Confidence is separately disclosed at 81/100.

Fair value (mid)

114 / share

72.5 – 165

Upside to FV

+8.7%

Confidence

81/100

Moat

6.5/10

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$20.0B
P/E (forward)	55.2x

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$2.08B	$2.50B	$2.76B	$3.25B	+15.9%
Gross profit	$1.42B	$1.76B	$1.92B	$2.26B	+16.7%
Operating income	$-577.5M	$-214.4M	$-179.2M	$-199.1M	—
Net income	$-623.5M	$-204.1M	$-1.03B	$-207.9M	—
EPS (diluted)	$-3.54	$-1.13	$-5.59	$-1.10	—
EBITDA	$-421.1M	$29.3M	$-789.3M	$52.4M	—
R&D	$394.2M	$426.9M	$431.2M	$523.0M	+9.9%
SG&A	$1.59B	$1.63B	$1.68B	$1.94B	+6.8%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AI	C3.ai, Inc.	1.4B	—	5.5x	-37.8%	+6.4%	-65.7%	Strong Buy
CRWD	CrowdStrike Holdings Inc.	182.7B	—	35.9x	-31.9%	+38.5%	+52.0%	Sell
ESTC	Elastic N.V.	6.7B	18.8x	3.9x	-10.0%	+23.4%	-27.5%	Strong Buy
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
SNY	Sanofi	109.3B	12.6x	2.0x	9.4%	+5.1%	-5.7%	Buy

Frequently asked questions

About this EXAS report

What is the latest published EXAS stock rating?

Exact Sciences Corp is shown with hold in the latest published report, analyzed 2026-05-13. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full EXAS analysis?

The full latest published report, analyzed 2026-05-13, lives at /stocks/EXAS/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for EXAS?

The latest published report analyzed 2026-05-13 frames EXAS around USD 72 to USD 165. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the EXAS page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-13). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Exact Sciences Corp (EXAS)

Coverage state: Latest published research available

Generate a fresh EXAS analysis

Our latest published analysis: EXAS rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · EXAS

Valuation

Next earnings

Sector percentile context

Deeper analysis on EXAS

Frequently asked questions